MARKET

MESO

MESO

Mesoblast
NASDAQ
15.20
+0.22
+1.47%
After Hours: 15.20 0 0.00% 16:10 05/22 EDT
OPEN
15.11
PREV CLOSE
14.98
HIGH
15.37
LOW
15.08
VOLUME
115.56K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
9.88
MARKET CAP
1.97B
P/E (TTM)
-20.6382
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MESO last week (0511-0515)?
Weekly Report · 5d ago
Largest borrow rate increases among liquid names
TipRanks · 05/13 15:20
Weekly Report: what happened at MESO last week (0504-0508)?
Weekly Report · 05/11 10:31
Weekly Report: what happened at MESO last week (0427-0501)?
Weekly Report · 05/04 10:28
Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)
TipRanks · 05/01 01:05
Mesoblast reports Q1 results
Seeking Alpha · 04/30 04:42
Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million
PUBT · 04/30 00:55
MESOBLAST REPORTS RYONCIL® NET REVENUES OF US$30.3M AND IMPROVED NET OPERATING CASH SPEND FOR THE QUARTER TO US$4.1 MILLION
Reuters · 04/30 00:55
More
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.